Detalhe da pesquisa
1.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet
; 400(10366): 1869-1881, 2022 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36354040
2.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab
; 25(9): 2634-2641, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37344954
3.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab
; 25(9): 2642-2649, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37264711
4.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Diabetes Obes Metab
; 25(4): 1080-1090, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36541037
5.
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab
; 22(10): 1886-1891, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32519795
6.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31984598
7.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-30293770
8.
Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward.
Am Heart J
; 168(3): 262-72, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25173536
9.
The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".
Ann Noninvasive Electrocardiol
; 19(1): 70-81, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24372708
10.
Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.
Phytother Res
; 28(9): 1308-14, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25340187
11.
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
Diabetes Ther
; 15(4): 819-832, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38402332
12.
Who visits a national park and what do they get out of it?: a joint visitor cluster analysis and travel cost model for Yellowstone National Park.
Environ Manage
; 52(4): 917-28, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23974903
13.
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Clin Pharmacokinet
; 61(7): 1057-1067, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35674880
14.
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
J Diabetes Sci Technol
; 16(2): 401-407, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33242998
15.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell Metab
; 34(9): 1234-1247.e9, 2022 09 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35985340
16.
Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions.
Pacing Clin Electrophysiol
; 34(9): 1116-27, 2011 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-21535038
17.
Successful Treatment of Brevibacterium Bacteremia Solely With Antimicrobial Therapy.
Cureus
; 13(6): e16004, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34336495
18.
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Clin Pharmacol Ther
; 110(6): 1467-1477, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34455583
19.
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Clin Pharmacol Ther
; 109(2): 310-318, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32866317
20.
Prone or lateral? Use of the Kocher-Langenbeck approach to treat acetabular fractures.
J Trauma
; 69(1): 137-41, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20016388